Back to Search Start Over

Correlating Efficacy in Rodent Cognition Models with in Vivo 5-Hydroxytryptamine1A Receptor Occupancy by a Novel Antagonist, (R)-N-(2-Methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane Carboxamide (WAY-101405)

Authors :
Deborah L. Smith
Annmarie L. Saab
Heidi van der Lee
Terrance H. Andree
Wayne E. Childers
Zoe A. Hughes
Meiyi Zhang
Thomas A. Comery
Suzan Aschmies
John Kao
Michael G. Kelly
Lee E. Schechter
Warren D. Hirst
Sharon Rosenzweig-Lipson
Lee A. Dawson
Stacey J. Sukoff Rizzo
Mark Day
Cesario O. Tio
Steven M. Grauer
Kelly Sullivan
Irene B. Feingold
Boyd L. Harrison
Source :
Journal of Pharmacology and Experimental Therapeutics. 325:134-145
Publication Year :
2008
Publisher :
American Society for Pharmacology & Experimental Therapeutics (ASPET), 2008.

Abstract

5-Hydroxytryptamine (5-HT) 1A receptors play an important role in multiple cognitive processes, and compelling evidence suggests that 5-HT 1A antagonists can reverse cognitive impairment. We have examined the therapeutic potential of a potent ( K i = 1.1 nM), selective (>100-fold), orally bioavailable, silent 5-HT 1A receptor antagonist ( K B = 1.3 nM) ( R )- N -(2-methyl-(4-indolyl-1-piperazinyl)-ethyl)- N -(2-pyridinyl)-cyclohexane carboxamide (WAY-101405). Oral administration of WAY-101405 was shown to be effective in multiple rodent models of learning and memory. In a novel object recognition paradigm, 1 mg/kg enhanced retention (memory) for previously learned information, and it was able to reverse the memory deficits induced by scopolamine. WAY-101405 (1 mg/kg) was also able to reverse scopolamine-induced deficits in a rat contextual fear conditioning model. In the Morris water maze, WAY-101405 (3 mg/kg) significantly improved learning in a paradigm of increasing task difficulty. In vivo microdialysis studies in the dorsal hippocampus of freely moving adult rats demonstrated that acute administration of WAY-101405 (10 mg/kg) increased extracellular acetylcholine levels. The selective radioligand [ 3 H]WAY-100635, administered i.v., was used for in vivo receptor occupancy studies, where WAY-101405 occupied 5-HT 1A receptors in the rat cortex, with an ED 50 value of 0.1 mg/kg p.o. Taken together, these studies demonstrate that WAY-101405 is a potent and selective, brain penetrant, orally bioavailable 5-HT 1A receptor “silent” antagonist that is effective in preclinical memory paradigms at doses where approximately 90% of the postsynaptic 5-HT 1A receptors are occupied. These results further support the rationale for use of this compound class in the treatment of cognitive dysfunction associated with psychiatric and neurological conditions.

Details

ISSN :
15210103 and 00223565
Volume :
325
Database :
OpenAIRE
Journal :
Journal of Pharmacology and Experimental Therapeutics
Accession number :
edsair.doi...........2afe00ebb88c6f091a09af7c416f2132
Full Text :
https://doi.org/10.1124/jpet.107.133082